Acquisition of Exclusive Manufacturing and Marketing Rights for DOTATOC
GARCHING, Germany, September 18, 2013 /PRNewswire/ –
- In-licensing of superior DOTA-Tyr3-octreotide - Pharmaceutical developmentfor treatment of NETs - Excellent pharmacokinetic properties
ITM Isotope Technologies Munich AG (ITM) today announced that it has entered into an
exclusive licensing agreement with Progenics Pharmaceuticals Inc. for pharmaceutical
development and commercialization of radiolabeled DOTA-conjugated somatostatin analogue
DOTA-[Tyr3]-octreotide (DOTATOC known as Edotreotide) for human oncology therapeutic use.
Radiolabeled DOTATOC is a superior agent for safe and highly effective radionuclide
therapy of somatostatin receptor positive tumors which offers excellent pharmacokinetic
properties and highest affinity to somatostatin receptor subtypes 2 and 5.
Scope of license agreement
The sublicense granted by Progenics Pharmaceuticals Inc. covers exclusive worldwide
manufacturing and marketing rights of DOTATOC and certain radiolabeled DOTATOC for human
oncology therapeutic use except the countries Albania, Algeria, Bahrain, Bulgaria, Cyprus,
Greece, Iran, Iraq, Kuwait, Lebanon, Oman, Qatar, Romania, Saudi Arabia, Syria, Turkey and
United Arab Emirates. Further terms of the agreement were not disclosed.
ITM affiliate ITG Isotope Technologies Garching GmbH will develop radiolabeled DOTATOC
for treatment of metastatic neuroendocrine tumors. In addition, DOTATOC as precursor is
now available and will be distributed in GMP quality in cooperation with a leading
supplier of advanced chemicals for nuclear medicine.
DOTATOC or Edotreotide is a superior synthetic somatostatin analog which binds
perfectly to somatostatin receptors predominantly overexpressed in neuroendocrine tumors
(NETs). NETs are rare kind of tumors which arise from neuroendocrine cells and may occur
in different parts of the body.
DOTA-chelated peptide Edotreotide exhibits excellent pharmacokinetic properties and
can be efficiently radiolabeled with medical radionuclides. Its excellent therapeutic
properties have been successfully started in various clinical trials.
About ITM Isotope Technologies Munich AG
The itm Group is the leading company for the development, production and worldwide
distribution of highly effective radionuclides for diagnosis and therapy as well as
radionuclide-based medical devices. Its commitment to shaping the future of theranostics
is built on robust platform technologies and innovative new generation radioisotopes which
assure safety, performance and security of supply!
Contacts Christopher Morin Manager Marketing & Corporate Communications Phone: +49-89-289-13915 Mail: Christopher.Morin@itg-garching.de Steffen Schuster CEO Phone: +49-89-289-13970 Mail: Steffen.Schuster@itm.ag
ITM Isotope Technologies Munich AG
Aufsichtsratsvorsitzender – Udo J. Vetter, Vorstandsvorsitzender – Steffen Schuster,
Sitz der Gesellschaft – Lichtenbergstr. 1, 85748 Garching – HG Muenchen – HRB 154944
SOURCE ITM Isotope Technologies Munich AG